(Q46886733)

26 December 2017

title

The Will Rogers phenomenon: the effect of different diagnostic criteria (English)

1 reference

26 December 2017

author name string

Maria Pia Sormani

series ordinal

1

1 reference

26 December 2017

publication date

1 December 2009

1 reference

26 December 2017

Journal of the Neurological Sciences

published in

1 reference

26 December 2017

volume

287 Suppl 1

1 reference

26 December 2017

page(s)

S46-9

1 reference

26 December 2017

Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Will Rogers phenomenon in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Conventional MRI in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

Rationale for early intervention with immunomodulatory treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971300-0

10.1016/S0022-510X(09)71300-0

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017